Your browser doesn't support javascript.
loading
Modulating Targeting of Poly(ethylene glycol) Particles to Tumor Cells Using Bispecific Antibodies.
Cui, Jiwei; Ju, Yi; Houston, Zachary H; Glass, Joshua J; Fletcher, Nicholas L; Alcantara, Sheilajen; Dai, Qiong; Howard, Christopher B; Mahler, Stephen M; Wheatley, Adam K; De Rose, Robert; Brannon, Paul T; Paterson, Brett M; Donnelly, Paul S; Thurecht, Kristofer J; Caruso, Frank; Kent, Stephen J.
Afiliação
  • Cui J; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria, 3010, Australia.
  • Ju Y; Key Laboratory of Colloid and Interface Chemistry of the Ministry of Education, School of Chemistry and Chemical Engineering, Shandong University, Jinan, Shandong, 250100, China.
  • Houston ZH; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria, 3010, Australia.
  • Glass JJ; Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Queensland, 4072, Australia.
  • Fletcher NL; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Centre for Advanced Imaging, The University of Queensland, St. Lucia, Queensland, 4072, Australia.
  • Alcantara S; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, 3010, Australia.
  • Dai Q; Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Queensland, 4072, Australia.
  • Howard CB; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Centre for Advanced Imaging, The University of Queensland, St. Lucia, Queensland, 4072, Australia.
  • Mahler SM; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, 3010, Australia.
  • Wheatley AK; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria, 3010, Australia.
  • De Rose R; Key Laboratory of Colloid and Interface Chemistry of the Ministry of Education, School of Chemistry and Chemical Engineering, Shandong University, Jinan, Shandong, 250100, China.
  • Brannon PT; Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Queensland, 4072, Australia.
  • Paterson BM; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Centre for Advanced Imaging, The University of Queensland, St. Lucia, Queensland, 4072, Australia.
  • Donnelly PS; ARC Training Centre for Biopharmaceutical Innovation, The University of Queensland, St. Lucia, Queensland, 4072, Australia.
  • Thurecht KJ; Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Queensland, 4072, Australia.
  • Caruso F; ARC Training Centre for Biopharmaceutical Innovation, The University of Queensland, St. Lucia, Queensland, 4072, Australia.
  • Kent SJ; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, 3010, Australia.
Adv Healthc Mater ; 8(9): e1801607, 2019 05.
Article em En | MEDLINE | ID: mdl-30868751
ABSTRACT
Low-fouling or "stealth" particles composed of poly(ethylene glycol) (PEG) display a striking ability to evade phagocytic cell uptake. However, functionalizing them for specific targeting is challenging. To address this challenge, stealth PEG particles prepared by a mesoporous silica templating method are functionalized with bispecific antibodies (BsAbs) to obtain PEG-BsAb particles via a one-step binding strategy for cell and tumor targeting. The dual specificity of the BsAbs-one arm binds to the PEG particles while the other targets a cell antigen (epidermal growth factor receptor, EGFR)-is exploited to modulate the number of targeting ligands per particle. Increasing the BsAb incubation concentration increases the amount of BsAb tethered to the PEG particles and enhances targeting and internalization into breast cancer cells overexpressing EGFR. The degree of BsAb functionalization does not significantly reduce the stealth properties of the PEG particles ex vivo, as assessed by their interactions with primary human blood granulocytes and monocytes. Although increasing the BsAb amount on PEG particles does not lead to the expected improvement in tumor accumulation in vivo, BsAb functionalization facilitates tumor cell uptake of PEG particles. This work highlights strategies to balance evading nonspecific clearance pathways, while improving tumor targeting and accumulation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polietilenoglicóis / Sistemas de Liberação de Medicamentos / Anticorpos Biespecíficos Limite: Animals / Humans Idioma: En Revista: Adv Healthc Mater Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polietilenoglicóis / Sistemas de Liberação de Medicamentos / Anticorpos Biespecíficos Limite: Animals / Humans Idioma: En Revista: Adv Healthc Mater Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Austrália